Literature DB >> 17998417

MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

D S Meier1, H L Weiner, C R G Guttmann.   

Abstract

BACKGROUND AND
PURPOSE: Formation of lesions in multiple sclerosis (MS) shows pronounced short-term fluctuation of MR imaging hyperintensity and size, a qualitatively known but poorly characterized phenomenon. With the use of time-series modeling of MR imaging intensity, our study relates the short-term dynamics of new T2 lesion formation to those of contrast enhancement and markers of long-term progression of disease.
MATERIALS AND METHODS: We analyzed 915 examinations from weekly to monthly MR imaging in 40 patients with MS using a time-series model, emulating 2 opposing processes of T2 prolongation and shortening, respectively. Patterns of activity, duration, and residual hyperintensity within new T2 lesions were measured and evaluated for relationships to disability, atrophy, and clinical phenotype in long-term follow-up.
RESULTS: Significant T2 activity was observed for 8 to 10 weeks beyond contrast enhancement, which suggests that T2 MR imaging is sensitive to noninflammatory processes such as degeneration and repair. Larger lesions showed longer subacute phases but disproportionally more recovery. Patients with smaller average peak lesion size showed trends toward greater disability and proportional residual damage. Higher rates of disability or atrophy were associated with subjects whose lesions showed greater residual hyperintensity.
CONCLUSION: Smaller lesions appeared disproportionally more damaging than larger lesions, with lesions in progressive MS smaller and of shorter activity than in relapsing-remitting MS. Associations of lesion dynamics with rates of atrophy and disability and clinical subtype suggest that changes in lesion dynamics may represent a shift from inflammatory toward degenerative disease activity and greater proximity to a progressive stage, possibly allowing staging of the progression of MS earlier, before atrophy or disability develops.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998417      PMCID: PMC8134267          DOI: 10.3174/ajnr.A0701

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Time-series analysis of MRI intensity patterns in multiple sclerosis.

Authors:  Dominik S Meier; Charles R G Guttmann
Journal:  Neuroimage       Date:  2003-10       Impact factor: 6.556

2.  MRI time series modeling of MS lesion development.

Authors:  Dominik S Meier; Charles R G Guttmann
Journal:  Neuroimage       Date:  2006-06-27       Impact factor: 6.556

3.  Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients.

Authors:  E W Willoughby; E Grochowski; D K Li; J Oger; L F Kastrukoff; D W Paty
Journal:  Ann Neurol       Date:  1989-01       Impact factor: 10.422

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

5.  Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

Authors:  Mark Keegan; Fatima König; Robyn McClelland; Wolfgang Brück; Yazmín Morales; Andreas Bitsch; Hillel Panitch; Hans Lassmann; Brian Weinshenker; Moses Rodriguez; Joseph Parisi; Claudia F Lucchinetti
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

6.  Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

Authors:  Richard A Rudick; Jar-Chi Lee; Jack Simon; Elizabeth Fisher
Journal:  Ann Neurol       Date:  2006-08       Impact factor: 10.422

7.  Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.

Authors:  Francesca Bagnato; Neal Jeffries; Nancy D Richert; Roger D Stone; Joan M Ohayon; Henry F McFarland; Joseph A Frank
Journal:  Brain       Date:  2003-06-23       Impact factor: 13.501

8.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

Authors:  Peter A Brex; Olga Ciccarelli; Jonathon I O'Riordan; Michael Sailer; Alan J Thompson; David H Miller
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

9.  Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability.

Authors:  J H van Waesberghe; W Kamphorst; C J De Groot; M A van Walderveen; J A Castelijns; R Ravid; G J Lycklama à Nijeholt; P van der Valk; C H Polman; A J Thompson; F Barkhof
Journal:  Ann Neurol       Date:  1999-11       Impact factor: 10.422

10.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  P D Molyneux; L Kappos; C Polman; C Pozzilli; F Barkhof; M Filippi; T Yousry; D Hahn; K Wagner; M Ghazi; K Beckmann; F Dahlke; N Losseff; G J Barker; A J Thompson; D H Miller
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

View more
  16 in total

1.  Longitudinal multiple sclerosis lesion segmentation: Resource and challenge.

Authors:  Aaron Carass; Snehashis Roy; Amod Jog; Jennifer L Cuzzocreo; Elizabeth Magrath; Adrian Gherman; Julia Button; James Nguyen; Ferran Prados; Carole H Sudre; Manuel Jorge Cardoso; Niamh Cawley; Olga Ciccarelli; Claudia A M Wheeler-Kingshott; Sébastien Ourselin; Laurence Catanese; Hrishikesh Deshpande; Pierre Maurel; Olivier Commowick; Christian Barillot; Xavier Tomas-Fernandez; Simon K Warfield; Suthirth Vaidya; Abhijith Chunduru; Ramanathan Muthuganapathy; Ganapathy Krishnamurthi; Andrew Jesson; Tal Arbel; Oskar Maier; Heinz Handels; Leonardo O Iheme; Devrim Unay; Saurabh Jain; Diana M Sima; Dirk Smeets; Mohsen Ghafoorian; Bram Platel; Ariel Birenbaum; Hayit Greenspan; Pierre-Louis Bazin; Peter A Calabresi; Ciprian M Crainiceanu; Lotta M Ellingsen; Daniel S Reich; Jerry L Prince; Dzung L Pham
Journal:  Neuroimage       Date:  2017-01-11       Impact factor: 6.556

2.  Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?

Authors:  Constantina Andrada Treabă; Rodica Bălaşa; Daniela Maria Podeanu; Iunius Paul Simu; Mircea Marian Buruian
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

3.  Magnetic resonance monitoring of lesion evolution in multiple sclerosis.

Authors:  Alex Rovira; Cristina Auger; Juli Alonso
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

4.  Experimental design and sample size considerations in longitudinal magnetic resonance imaging-based biomarker detection for multiple sclerosis.

Authors:  Menghan Hu; Matthew K Schindler; Blake E Dewey; Daniel S Reich; Russell T Shinohara; Ani Eloyan
Journal:  Stat Methods Med Res       Date:  2020-02-19       Impact factor: 3.021

Review 5.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

6.  Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques.

Authors:  F Durand-Dubief; B Belaroussi; J P Armspach; M Dufour; S Roggerone; S Vukusic; S Hannoun; D Sappey-Marinier; C Confavreux; F Cotton
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

7.  A new metric for detecting change in slowly evolving brain tumors: validation in meningioma patients.

Authors:  Kilian M Pohl; Ender Konukoglu; Sebastian Novellas; Nicholas Ayache; Andriy Fedorov; Ion-Florin Talos; Alexandra Golby; William M Wells; Ron Kikinis; Peter M Black
Journal:  Neurosurgery       Date:  2011-03       Impact factor: 4.654

8.  Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation.

Authors:  Ana Paula Kallaur; Josiane Lopes; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche; Elaine Regina Delicato de Almeida; Helena Kaminami Morimoto; Wildea Lice Carvalho Jennings de Pereira; Daniele Frizon Alfieri; Sueli Donizete Borelli; Domacio Ramon Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-09-24       Impact factor: 5.590

Review 9.  Imaging small vessel-associated white matter changes in aging.

Authors:  D H Salat
Journal:  Neuroscience       Date:  2013-12-06       Impact factor: 3.590

Review 10.  MRI in multiple sclerosis: current status and future prospects.

Authors:  Rohit Bakshi; Alan J Thompson; Maria A Rocca; Daniel Pelletier; Vincent Dousset; Frederik Barkhof; Matilde Inglese; Charles R G Guttmann; Mark A Horsfield; Massimo Filippi
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.